| Michael David Macias, LMFT,LMHC,NCC,CSAC | |
|
549th Hospital Center, Unit #15245, Apo, AP 96271 | |
| (315) 737-5668 | |
| Not Available |
| Full Name | Michael David Macias |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 549th Hospital Center, Apo, Armed Forces Pacific |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417509589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC1900X | Psychologist - Counseling | MHC-600 (Hawaii) | Secondary |
| 106H00000X | Marriage & Family Therapist | 616 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael David Macias, LMFT,LMHC,NCC,CSAC Psc 400 Box 3232, Apo, AP 96273-0033 Ph: () - | Michael David Macias, LMFT,LMHC,NCC,CSAC 549th Hospital Center, Unit #15245, Apo, AP 96271 Ph: (315) 737-5668 |
News Archive
Future Medicine Ltd has today announced the launch of Neuropsychiatry – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world. Neuropsychiatry is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and
Ronald Valdesarri, HHS deputy assistant secretary for health, infectious diseases, discusses a recent "two-day workshop on 'Modeling and Evidence-Based Decision Making' sponsored by amfAR, the Foundation for AIDS Research and cosponsored by the Kaiser Family Foundation, the National Alliance of State and Territorial AIDS Directors, and the Urban Coalition for HIV/AIDS Prevention Services" in this AIDS.gov blog post.
Rapid medical tests that can be analyzed in close proximity to patients in professional settings comprise the fastest growing segment of the global $37.5B in-vitro diagnostics industry, according to a new global review of the point-of-care (POC) diagnostics industry.
Nanobiotix has announced that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology.
Wolters Kluwer Health today announced that it has completed the acquisition of Lexi-Comp, Inc., a leading provider of drug information and clinical content for pharmacists, clinicians and hospitals internationally.
› Verified 5 days ago